Evaluation of the Cost and Effectiveness in the First-line Treatment of Advanced Renal Cell Cancer With Sunitinib Compared to Interferon-alfa in Finland.
N/A
18 Years
85 Years
18 Years
85 Years
Open (Enrolling)
Both
Neoplasms, Renal Cell Carcinoma
Both
Neoplasms, Renal Cell Carcinoma
Trial Information
Evaluation of the Cost and Effectiveness in the First-line Treatment of Advanced Renal Cell Cancer With Sunitinib Compared to Interferon-alfa in Finland.
Inclusion Criteria:
- Clinically indicated first-line sunitinib treatment for advanced RCC.
- Informed consent obtained.
Exclusion Criteria:
- Unable to complete HRQoL forms.
- Not consenting to collecting register data.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Incremental cost per incremental time to treatment failure (TTF) in first-line treatment
Outcome Time Frame:
1 month
Safety Issue:
No
Authority:
Finland: Finnish Medicines Agency
Study ID:
R09045
NCT ID:
NCT00980213
Start Date:
September 2009
Completion Date:
December 2015
Related Keywords:
- Neoplasms
- Renal Cell Carcinoma
- renal cell cancer
- sunitinib
- costs
- quality of life
- Neoplasms
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
